These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24821853)

  • 1. The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.
    Malaviya AP; Ledingham J; Bloxham J; Bosworth A; Buch M; Choy E; Cope A; Isaacs J; Marshall D; Wright G; Ostör AJ; ;
    Rheumatology (Oxford); 2014 Jul; 53(7):1344-6. PubMed ID: 24821853
    [No Abstract]   [Full Text] [Related]  

  • 2. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
    Nasonov EL
    Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab.
    Venkiteshwaran A
    MAbs; 2009; 1(5):432-8. PubMed ID: 20065633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The importance of cytokine profile characteristics for evaluating the therapeutic effectiveness of monoclonal antibodies against IL-6 receptors in patients with rheumatoid arthritis].
    Avdeev AS; Novikov AA; Aleksandrova EN; Panasiuk EIu; Nasonov EL
    Klin Med (Mosk); 2014; 92(1):28-34. PubMed ID: 25265656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IL-6 targeting therapy to retard structural joint damage in patients with rheumatoid arthritis].
    Nishimoto N
    Clin Calcium; 2009 Mar; 19(3):425-31. PubMed ID: 19252253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous tocilizumab for the treatment of rheumatoid arthritis.
    Mitchell E; Jones G
    Expert Rev Clin Immunol; 2016; 12(2):103-14. PubMed ID: 26629984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    Kivitz A; Olech E; Borofsky M; Zazueta BM; Navarro-Sarabia F; Radominski SC; Merrill JT; Rowell L; Nasmyth-Miller C; Bao M; Wright S; Pope JE
    Arthritis Care Res (Hoboken); 2014 Nov; 66(11):1653-61. PubMed ID: 24942540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced hypereosinophilia related to tocilizumab therapy for rheumatoid arthritis.
    Morrisroe K; Wong M
    Rheumatology (Oxford); 2015 Nov; 54(11):2113-4. PubMed ID: 26224305
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab for the treatment of rheumatoid arthritis.
    Tanaka T; Ogata A; Narazaki M
    Expert Rev Clin Immunol; 2010 Nov; 6(6):843-54. PubMed ID: 20979549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interlukin-6 receptor inhibitor tocilizumab: a new treatment option in rheumatoid arthritis?
    Johnson J; Wang MY
    Neurosurgery; 2008 Aug; 63(2):N8. PubMed ID: 18797345
    [No Abstract]   [Full Text] [Related]  

  • 12. Inhibiting interleukin-6 in rheumatoid arthritis.
    Choy E
    Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cat-scratch fever and lymphadenopathy in a rheumatoid arthritis patient on tocilizumab.
    Singh N; Sinclair LL; IJdo J
    J Clin Rheumatol; 2015 Jan; 21(1):40. PubMed ID: 25539435
    [No Abstract]   [Full Text] [Related]  

  • 14. Tocilizumab (Actemra).
    Sheppard M; Laskou F; Stapleton PP; Hadavi S; Dasgupta B
    Hum Vaccin Immunother; 2017 Sep; 13(9):1972-1988. PubMed ID: 28841363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma.
    Ingegnoli F; Tourlaki A; Gualtierotti R
    Clin Drug Investig; 2014 Feb; 34(2):159-61. PubMed ID: 24307431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-6 inhibition--tolerability profile and clinical implications.
    Strand V; Yazici Y
    Bull NYU Hosp Jt Dis; 2007; 65 Suppl 1():S21-4. PubMed ID: 17708741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical benefits of anti-human IL-6 receptor antibody therapy].
    Nishimoto N
    Clin Calcium; 2007 Apr; 17(4):562-8. PubMed ID: 17404486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab.
    Ogata A; Morishima A; Hirano T; Hishitani Y; Hagihara K; Shima Y; Narazaki M; Tanaka T
    Ann Rheum Dis; 2011 Jun; 70(6):1164-5. PubMed ID: 20980285
    [No Abstract]   [Full Text] [Related]  

  • 19. Osteoprotegerin expression in bone marrow by treatment with tocilizumab in rheumatoid arthritis.
    Kanbe K; Nakamura A; Inoue Y; Hobo K
    Rheumatol Int; 2012 Sep; 32(9):2669-74. PubMed ID: 21789615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study.
    Tanaka E; Inoue E; Hoshi D; Shimizu Y; Kobayashi A; Sugimoto N; Shidara K; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Yamanaka H
    Mod Rheumatol; 2015 Jul; 25(4):503-13. PubMed ID: 25547018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.